m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03136)
Name
B-623
Synonyms
149732-37-6
    Click to Show/Hide
Status
Investigative
Structure
Formula
C18H14N2O2S
InChI
1S/C18H14N2O2S/c19-18(20)17-9-13-12(2-1-3-16(13)23-17)6-4-11-5-7-14-15(8-11)22-10-21-14/h1-9H,10H2,(H3,19,20)/b6-4+
InChIKey
BGFUKOBHJOFLNH-GQCTYLIASA-N
PubChem CID
9820186
TTD Drug ID
D05DNW
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Urokinase-type plasminogen activator (PLAU)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Urokinase-type plasminogen activator (PLAU) is a therapeutic target for B-623. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of B-623 through regulating the expression of Urokinase-type plasminogen activator (PLAU). [1], [2]
References
Ref 1 METTL3 promotes colorectal cancer metastasis by stabilizing PLAU mRNA in an m6A-dependent manner. Biochem Biophys Res Commun. 2022 Jul 23;614:9-16. doi: 10.1016/j.bbrc.2022.04.141. Epub 2022 May 6.
Ref 2 Natural and synthetic inhibitors of the tumor-associated serine protease urokinase-type plasminogen activator. Adv Exp Med Biol. 2000;477:331-41. doi: 10.1007/0-306-46826-3_36.